LAUSR

Inhibitors of Sodium-Glucose transporter (SGLT-2) are among the newest pharmacotherapeutics to be evaluated for the management of 2019-Coronavirus disease (COVID-19). Few hypotheses like reduced lactatemia, inhibition of Na-H exchanger, reduction of proinflammatory cytokines, augmentation of alternative rennin-angiotensin-aldosterone pathway, pleotropic organ protective effects etc have been put forward to explain the possible effects of SGLT-2 inhibitors in mitigating the disease severity of COVID-19. With this background a single placebo-controlled randomized trial involving dapagliflozin has been started recently among COVID-19 patients with mild to moderate severity. Using SGLT-2 inhibitors among hospitalized patients amidst risk of euglycemic diabetic ketoacidosis and peripheral arterial disease is a matter of concern.